摘要
目的:了解武汉地区医院碳青霉烯类药的应用情况及趋势。方法:对武汉地区32家医院2009-2011年碳青霉烯类药的销售金额、用药频度(DDDs)和日均费用(DDC)等进行回顾性统计、分析。结果:该地区医院所用碳青霉烯类药的总销售金额2010年达7528.80万元,较2009年(5216.44万元)增长30.71%,2011年(7478.71万元)较2010年下降0.67%。3年来DDDs持续增长,始终居于首位的是美罗培南,帕尼培南/倍他米隆的DDDs最低。各药的DDC相对稳定,其中比阿培南的DDC最高(约950元),法罗培南最低(约34元)。结论:抗菌药物专项整治活动的开展,在一定程度上限制了该地区碳青霉烯类药的使用;应继续加强抗菌药物的监管力度,确保碳青霉烯类药在临床的合理应用。
OBJECTIVE： To investigate the application and tendency of carbapenems in hospitals from Wuhan area. METHODS： The application of carbapenems in 32 hospitals of Wuhan area druing 2009-2011 was analyzed statistically in terms of consumption sum, DDDs and DDC, etc. RESULTS： Total consumption sum of carbapenems reached 75 288 000 yuan in 2010, increasing by 30.71% compared to 2009. Compared to 2010, that in 2011 （74 787 100 yuan） decreased by 0.67%. DDDs sustained growth in 3 years, and meropenem always ranked the first place ; DDDs of panipenem/betamipron were the lowest. DDC of drugs was relatively stable, among which the highest was biapenem （950 yuan） , the lowest was faropenem （34 yuan）. CONCLUSIONS. Since the special rectification of antibiotics is carried out, carbapenems use is limited in Wuhan area to some extent. The government should continue to strengthen the management of antibiotics to ensure rational use of carbapenems in the clinic.
出处
《中国药房》
CAS
CSCD
2013年第10期868-870,共3页
China Pharmacy
